
{
  "documentMetadata": {
    "title": "Endocarditis, Gonococcal",
    "lastUpdated": "2023-11-14",
    "sourceFile": "Endocarditis_ Gonococcal.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Specific therapy for endocarditis with positive blood cultures for N. gonorrhoeae.",
        "Signs and symptoms of endocarditis.",
        "Gonococcal endocarditis may occur in the absence of concomitant urogenital symptoms (Infection 42:425, 2014).",
        "Pharyngeal and rectal infection may be asymptomatic and difficult to eradicate (test for cure in cases of pharyngeal infection)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Neisseria gonorrhoeae"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Ceftriaxone",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q24h"
          }
        ],
        "durationDetail": {
          "fixedDuration": "4 weeks"
        }
      }
    },
    {
        "type": "partnerManagement",
        "partnerManagementData": {
            "action": "Treat sex partners"
        }
    },
    {
        "type": "diagnosticTest",
        "diagnosticTestData": {
            "name": "Test patient for HIV, syphilis and Chlamydia"
        }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "paragraph",
      "text": "None"
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Ceftriaxone resistance in N. gonorrhoeae has been reported (Antimicrob Agents Chemother 55:3538, 2011; Emerg Infect Dis 2018; 24:735, 2018); determine susceptibility of any isolate recovered.",
        "For extensively resistant species Ertapenem treatment can be considered (European 2020 IUSTI guidelines)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Severe valve destruction may occur.",
        "2021 CDC STD treatment recommendations MMWR Recomm Rep 70 (RR-4):1 2021 are for Ceftriaxone 1-2 gm IV every 12 hours for at least 4 weeks but few studies to determine optimal treatment.",
        "As of 2020 (MMWR 69:1911 2020) CDC no longer recommends treating gonococcal infections presumptively for Chlamydia"
      ]
    }
  ]
}
